CDC Reports on Postmarketing Safety of the Rotateq Vaccine

The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention (CDC) have monitored the postmarketing safety of Rotateq through the Vaccine Adverse Event Reporting System and the Vaccine Safety Datalink. The CDC determined that there was not a statistically significant risk of intussusception within 42 days after the administration of the vaccine.